Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation

Am J Epidemiol. 2022 Jan 24;191(2):331-340. doi: 10.1093/aje/kwab242.

Abstract

To examine methodologies that address imbalanced treatment switching and censoring, 6 different analytical approaches were evaluated under a comparative effectiveness framework: intention-to-treat, as-treated, intention-to-treat with censor-weighting, as-treated with censor-weighting, time-varying exposure, and time-varying exposure with censor-weighting. Marginal structural models were employed to address time-varying exposure, confounding, and possibly informative censoring in an administrative data set of adult patients who were hospitalized with acute coronary syndrome and treated with either clopidogrel or ticagrelor. The effectiveness endpoint included first occurrence of death, myocardial infarction, or stroke. These methodologies were then applied across simulated data sets with varying frequencies of treatment switching and censoring to compare the effect estimate of each analysis. The findings suggest that implementing different analytical approaches has an impact on the point estimate and interpretation of analyses, especially when censoring is highly unbalanced.

Keywords: acute coronary syndrome; clopidogrel; comparative effectiveness research; selection bias; simulation; ticagrelor.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome / complications
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / mortality
  • Adult
  • Aged
  • Clopidogrel / therapeutic use
  • Comparative Effectiveness Research
  • Computer Simulation
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • Intention to Treat Analysis
  • Latent Class Analysis
  • Male
  • Middle Aged
  • Myocardial Infarction / etiology
  • Myocardial Infarction / mortality
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Selection Bias*
  • Stroke / etiology
  • Stroke / mortality
  • Ticagrelor / therapeutic use
  • Treatment Outcome
  • Treatment Switching*

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticagrelor